{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:36:54Z","timestamp":1776793014335,"version":"3.51.2"},"reference-count":97,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Transcatheter structural heart interventions, including aortic, mitral and tricuspid valve replacement or repair, and patent foramen ovale, atrial septal defect, and left atrial appendage closure, have dramatically expanded over the past two decades, providing substantial improvements in both clinical outcomes and quality of life. These interventions are performed in a high-risk patient population, which is at risk for both thrombotic and bleeding complications. The introduction of prosthetic devices into the arterial or venous circulation under heterogeneous hemodynamic conditions inevitably increases the risk for thrombotic events and thromboembolic complications. Consequently, the selection of antithrombotic therapy (AT) regimen and its duration is complex and should be tailored to each patient\u2019s risk profile, balancing the expected risk and benefits. This state-of-the-art review critically examines the thrombotic risks inherent to transcatheter structural heart interventions, synthesizes available evidence and current guidelines recommendations on antithrombotic management, and defines persisting gaps in knowledge while discussing the most relevant ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/jcm15083175","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:10:44Z","timestamp":1776787844000},"page":"3175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Thrombotic Therapy Following Transcatheter Structural Heart Intervention"],"prefix":"10.3390","volume":"15","author":[{"given":"Francesco","family":"Tartaglia","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"The Heart Center, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2628-8480","authenticated-orcid":false,"given":"Giulia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Gitto","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif A.","family":"Khokhar","sequence":"additional","affiliation":[{"name":"The Heart Center, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Soriente","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Pasquale","family":"Leone","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Regazzoli","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"de Backer","sequence":"additional","affiliation":[{"name":"The Heart Center, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-4046","authenticated-orcid":false,"given":"Antonio","family":"Mangieri","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6967","authenticated-orcid":false,"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"},{"name":"IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"46","author":"Praz","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_2","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.jacc.2019.08.1032","article-title":"Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement","volume":"74","author":"Mangieri","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.4244\/EIJ-D-23-01087","article-title":"Cerebrovascular events after transcatheter aortic valve implantation","volume":"20","author":"Reddy","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.4244\/EIJ-D-24-00066","article-title":"Management of complications after valvular interventions","volume":"21","author":"Bansal","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2018.01.066","article-title":"Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement","volume":"71","author":"Jabbour","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","article-title":"Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research","volume":"77","author":"Piazza","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ehjci\/jex181","article-title":"Transcatheter aortic valve thrombosis: Incidence, clinical presentation and long-term outcomes","volume":"19","author":"Franzone","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4244\/EIJ-D-25-00523","article-title":"Incidence, predictors, and clinical impact of hypoattenuating leaflet thickening following SAPIEN 3 Ultra RESILIA implantation","volume":"21","author":"Ishizu","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"oeae085","DOI":"10.1093\/ehjopen\/oeae085","article-title":"Valvular and perivalvular thrombosis following self-expandable aortic valve replacement: Analysis of 100 multi-detector computed tomography scans","volume":"4","author":"Moscarelli","year":"2024","journal-title":"Eur. Heart J. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2024.05.064","article-title":"Treatment of Transcatheter Aortic Valve Thrombosis","volume":"84","author":"Adrichem","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jcin.2021.09.019","article-title":"Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement","volume":"14","author":"Bogyi","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/j.jcin.2023.10.024","article-title":"Frequency, Predictors, and Clinical Impact of Valvular and Perivalvular Thrombus After Transcatheter Aortic Valve Replacement","volume":"16","author":"Choi","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: An observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jcin.2022.04.018","article-title":"Long-Term Follow-Up of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement","volume":"15","author":"Hein","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1067","DOI":"10.4244\/EIJ-D-17-00373","article-title":"Subclinical leaflet thickening and stent frame geometry in self-expanding transcatheter heart valves","volume":"13","author":"Fuchs","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jcin.2025.02.013","article-title":"Clinical Impact of Midframe Underexpansion Following TAVR Using a Self-Expanding Transcatheter Heart Valve","volume":"18","author":"Kim","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.jbiomech.2016.10.050","article-title":"Transcatheter aortic valves produce unphysiological flows which may contribute to thromboembolic events: An in-vitro study","volume":"49","author":"Ducci","year":"2016","journal-title":"J. Biomech."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.4244\/EIJ-D-25-01106","article-title":"Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli","volume":"22","author":"Backer","year":"2026","journal-title":"EuroIntervention"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911425","article-title":"Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement","volume":"15","author":"Montalescot","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual Antiplatelet Therapy Versus Aspirin Alone in Patients Undergoing Transcatheter Aortic Valve Implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement with a Balloon-Expandable Valve","volume":"10","author":"Masson","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e009983","DOI":"10.1161\/CIRCINTERVENTIONS.120.009983","article-title":"Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients","volume":"14","author":"Rogers","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: The ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR","volume":"385","author":"Unverdorben","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCINTERVENTIONS.108.796094","article-title":"Ingrowths of a Percutaneously Implanted Aortic Valve Prosthesis (CoreValve) in a Patient with Severe Aortic Stenosis","volume":"1","author":"Linke","year":"2008","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacc.2022.11.050","article-title":"Bleeding Events After Transcatheter Aortic Valve Replacement","volume":"81","author":"Avvedimento","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.jacc.2021.09.855","article-title":"Trends in Transcatheter and Surgical Aortic Valve Replacement Among Older Adults in the United States","volume":"78","author":"Mori","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","article-title":"Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease","volume":"42","author":"Sibbing","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ehjqcco\/qcaf003","article-title":"Antithrombotic therapy following transcatheter aortic valve implantation: A Danish nationwide study","volume":"11","author":"Vistisen","year":"2025","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/ehjcvp\/pvaf049","article-title":"Single vs. dual antiplatelet therapy in patients with severe peripheral arterial disease undergoing transcatheter aortic valve implantation: Insights from the Hostile registry","volume":"11","author":"Galli","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcin.2024.10.055","article-title":"Timing and Outcomes of PCI in Conjunction with TAVR with Balloon-Expandable Valves","volume":"18","author":"Dhoble","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcin.2024.11.008","article-title":"See, Touch, Feel: The Need for Modern PCI in TAVR Patients","volume":"18","author":"Stefanini","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e006730","DOI":"10.1161\/CIRCINTERVENTIONS.118.006730","article-title":"Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation","volume":"11","author":"Simonato","year":"2018","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.4244\/EIJ-D-24-00711","article-title":"Prognostic implications and predictive factors of subclinical leaflet thrombosis following valve-in-valve transcatheter aortic valve implantation","volume":"21","author":"Nagasaka","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.jcin.2025.09.018","article-title":"Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure","volume":"18","author":"Bendandi","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e010097","DOI":"10.1161\/CIRCINTERVENTIONS.120.010097","article-title":"Aspirin Versus Clopidogrel as Single Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry","volume":"14","author":"Kobari","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcin.2022.10.010","article-title":"No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement","volume":"16","author":"Kobari","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients","volume":"380","author":"Mack","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients","volume":"364","author":"Smith","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcin.2024.09.039","article-title":"Hemodynamic Valve Deterioration After Transcatheter Aortic Valve Replacement","volume":"18","author":"Alaour","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Trimaille, A., Hernando del Portillo, J., Giuliani, C., Vidal-Cales, P., Salaun, E., Avvedimento, M., and Rod\u00e9s-Cabau, J. (2025). Impact of Anticoagulation on Long-Term Bioprosthesis Durability After Transcatheter Aortic Valve Replacement. Can. J. Cardiol., Published online.","DOI":"10.1016\/j.shj.2025.100786"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.123.067312","article-title":"Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients with Atrial Fibrillation","volume":"149","author":"Kapadia","year":"2024","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jacc.2023.09.831","article-title":"Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures","volume":"83","author":"Lakkireddy","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa2407794","article-title":"Continuation versus Interruption of Oral Anticoagulation during TAVI","volume":"392","author":"Bor","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jamacardio.2024.2454","article-title":"Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation","volume":"9","author":"Vriesendorp","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2024.10.002","article-title":"Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves\u2014The NOTION-4 trial","volume":"279","author":"Thuraiaiyah","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous Repair or Surgery for Mitral Regurgitation","volume":"364","author":"Feldman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter Mitral-Valve Repair in Patients with Heart Failure","volume":"379","author":"Stone","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e015298","DOI":"10.1161\/CIRCINTERVENTIONS.125.015298","article-title":"TMVR for the Treatment of Mitral Regurgitation: A State-of-the-Art Review","volume":"18","author":"Tartaglia","year":"2025","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jacc.2021.08.060","article-title":"2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients with Severe Symptomatic Mitral Regurgitation","volume":"78","author":"Muller","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jacc.2023.10.031","article-title":"Comparison of Direct Oral Anticoagulants vs Vitamin K Antagonists After Transcatheter Mitral Valve Replacement","volume":"83","author":"Himbert","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4244\/EIJ-D-20-00991","article-title":"Predictors and clinical impact of thrombosis after transcatheter mitral valve implantation using balloon-expandable bioprostheses","volume":"16","author":"Urena","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.jcin.2023.10.001","article-title":"1-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement","volume":"16","author":"Zahr","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/S0140-6736(25)02073-2","article-title":"Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: A prospective, multicountry, single-arm trial","volume":"406","author":"Guerrero","year":"2025","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"133777","DOI":"10.1016\/j.ijcard.2025.133777","article-title":"Transcatheter therapies for tricuspid regurgitation: A meta-analysis of randomized trials","volume":"441","author":"Tartaglia","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter Repair for Patients with Tricuspid Regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacc.2023.05.008","article-title":"Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice","volume":"82","author":"Lurz","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.jcin.2025.07.016","article-title":"Early Leaflet Thrombosis Following EVOQUE Transcatheter Tricuspid Valve Replacement","volume":"18","author":"Skalidis","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcin.2025.10.026","article-title":"Hypoattenuated Leaflet Thickening and Reduced Leaflet Motion After Transcatheter Tricuspid Valve Replacement","volume":"19","author":"Kempton","year":"2026","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa2401918","article-title":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation","volume":"392","author":"Hahn","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jcin.2024.12.030","article-title":"Transcatheter Tricuspid Valve Replacement with the Novel System","volume":"18","author":"Pan","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103698","DOI":"10.1016\/j.jaccas.2025.103698","article-title":"Bioprosthetic Valve Thrombosis After Transcatheter Tricuspid Valve Replacement","volume":"30","author":"Malvy","year":"2025","journal-title":"JACC Case Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke","volume":"377","author":"Kasner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic Stroke and High-Risk Patent Foramen Ovale","volume":"71","author":"Lee","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ehjcvp\/pvad023","article-title":"Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure","volume":"9","author":"Guedeney","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamacardio.2020.4297","article-title":"Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure","volume":"6","author":"Horlick","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/ehy649","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","volume":"40","author":"Pristipino","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_78","first-page":"100039","article-title":"SCAI Guidelines for the Management of Patent Foramen Ovale","volume":"1","author":"Kavinsky","year":"2022","journal-title":"J. Soc. Cardiovasc. Angiogr. Interv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and Clinical Impact of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","article-title":"Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients with Atrial Fibrillation","volume":"79","author":"Freeman","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous Left Atrial Appendage Closure vs. Warfarin for Atrial Fibrillation","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation Versus Long-Term Warfarin Therapy","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-Related Thrombus After Left Atrial Appendage Closure","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year Outcomes After Left Atrial Appendage Closure","volume":"70","author":"Reddy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left Atrial Appendage Closure with the Watchman Device in Patients with a Contraindication for Oral Anticoagulation","volume":"61","author":"Reddy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.121.057859","article-title":"Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial","volume":"145","author":"Galea","year":"2022","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e008481","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa2513310","article-title":"Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation","volume":"394","author":"Landmesser","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Doshi, S.K., Kar, S., Nair, D.G., Waggoner, T., Agarwal, H., Moussavian, M., Kashani, A., Oza, S., Feldman, L., and Sadhu, A. (2026). Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. N. Engl. J. Med., epub ahead of print.","DOI":"10.1056\/NEJMoa2517213"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2019.12.040","article-title":"The NCDR Left Atrial Appendage Occlusion Registry","volume":"75","author":"Freeman","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion","volume":"14","author":"Magnocavallo","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/eurheartj\/ehv730","article-title":"Implant success and safety of left atrial appendage closure with the WATCHMAN device: Peri-procedural outcomes from the EWOLUTION registry","volume":"37","author":"Boersma","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.4244\/EIJ-D-18-00344","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: One-year follow-up from the prospective global Amulet observational registry","volume":"14","author":"Landmesser","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcin.2019.04.004","article-title":"Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure with WATCHMAN","volume":"12","author":"Wong","year":"2019","journal-title":"JACC Cardiovasc. Interv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:37:27Z","timestamp":1776789447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":97,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15083175"],"URL":"https:\/\/doi.org\/10.3390\/jcm15083175","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}